TRPM3-related neurodevelopmental disorder

Last updated
TRPM3-related neurodevelopmental disorder
Specialty Neurology

TRPM3-related neurodevelopmental disorder [1] is a monogenetic developmental and epileptic encephalopathy that affects the central nervous system. [2] The broad phenotype includes global developmental delay, intellectual disability, epilepsy, musculoskeletal anomalies, altered pain perception, ataxia, hypotonia, nystagmus, and cerebellar atrophy. [2] [3] [4]

Contents

Signs and Symptoms

The earliest sign for TRPM3-related neurodevelopmental disorder is usually congenital hypotonia. Infant feeding issues including dysphagia and gastroesophageal reflux are also reported. [1] Global developmental delay is nearly always present along with mild-to-severe intellectual disability. [1] [2] [4] Epilepsy is reported in 50% of cases. [1] [2]

Other signs of TRPM3-related neurodevelopmental disorder are dysmorphic facial features, scoliosis, hip dysplasia, exotropia, strabismus, nystagmus, ataxia, and altered pain perception. [1] [2]

Cause

TRPM3-related neurodevelopmental disorder is an autosomal dominant genetic disorder. [1] It is caused by missense mutations in the TRPM3 gene. [1] [2] Since the general population has numerous truncating variants and microdeletions throughout TRPM3, the underlying mechanism for neurodevelopmental disorder is not haploinsufficiency. [3]

Research has shown that the disease-associated mutations lead to a gain-of-function. The mutations produce increased basal activity of the TRPM3 ion channel as well as increased response to chemical and noxious heat stimuli. The gain-of-function results in increased intracellular Ca2+. It is possible that this increased channel activity and/or Ca2+ induced nerve damage could be the underlying mechanism of the disease. [5] [6] [2]

Diagnosis

Diagnosis is made through genetic testing using an intellectual disability or epilepsy multigene panel that includes TRPM3 or whole exome sequencing. [1] Following identification of a mutation in the TRPM3 gene, alterations in channel activity are evaluated using electrophysiological assays and calcium imaging [2] [6] [5]

Treatment

There is currently no known cure or treatment for TRPM3-related neurodevelopmental disorder. Treatment for individual manifestations of symptoms may follow standard of care (anti-epileptic medication for seizures, physical therapy, occupational therapy, speech therapy, etc). [1]

A single study points to the anti-convulsant drug primidone as an off label therapeutic. [7] Primidone is a known TRPM3 antagonist. [8]

Prognosis

Life span is apparently not impacted by TRPM3-related neurodevelopmental disorder. Not enough data currently exists to understand the disease progression. [1]

Epidemiology

There are currently >30 reported cases of TRPM3-related neurodevelopmental disorder. [1] [4] [2] [9] [10] [11] It is unknown what the prevalence of this disorder is worldwide.



Other Resources

TRPM3 Foundation

Related Research Articles

<span class="mw-page-title-main">Unibrow</span> Presence of abundant hair between the eyebrows

A unibrow is a single eyebrow created when the two eyebrows meet in the middle above the bridge of the nose. The hair above the bridge of the nose is of the same color and thickness as the eyebrows, such that they converge to form one uninterrupted line of hair.

<span class="mw-page-title-main">2-Hydroxyglutaric aciduria</span> Medical condition

2-hydroxyglutaric aciduria is a rare neurometabolic disorder characterized by the significantly elevated levels of hydroxyglutaric acid in one's urine. It is either autosomal recessive or autosomal dominant.

Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy (SMEI), is an autosomal dominant genetic disorder which causes a catastrophic form of epilepsy, with prolonged seizures that are often triggered by hot temperatures or fever. It is very difficult to treat with anticonvulsant medications. It often begins before one year of age, with six months being the age that seizures, char­ac­ter­ized by prolonged convulsions and triggered by fever, usually begin.

<span class="mw-page-title-main">TRPM3</span> Protein-coding gene in the species Homo sapiens

Transient receptor potential cation channel subfamily M member 3 is a protein that in humans is encoded by the TRPM3 gene.

Ohtahara syndrome (OS), also known as early infantile epileptic encephalopathy (EIEE) is a progressive epileptic encephalopathy. The syndrome is outwardly characterized by tonic spasms and partial seizures within the first few months of life, and receives its more elaborate name from the pattern of burst activity on an electroencephalogram (EEG). It is an extremely debilitating progressive neurological disorder, involving intractable seizures and severe intellectual disabilities. No single cause has been identified, although in many cases structural brain damage is present.

<span class="mw-page-title-main">CHD2</span> Protein-coding gene in the species Homo sapiens

Chromodomain-helicase-DNA-binding protein 2 is an enzyme that in humans is encoded by the CHD2 gene.

<span class="mw-page-title-main">Pitt–Hopkins syndrome</span> Medical condition

Pitt–Hopkins syndrome (PTHS) is a rare genetic disorder characterized by developmental delay, epilepsy, distinctive facial features, and possible intermittent hyperventilation followed by apnea. Pitt-Hopkins syndrome can be marked by intellectual disabilities as well as problems with socializing. It is part of the clinical spectrum of Rett-like syndromes.

Epilepsy-intellectual disability in females also known as PCDH19 gene-related epilepsy or epileptic encephalopathy, early infantile, 9 (EIEE9), is a rare type of epilepsy that affects predominately females and is characterized by clusters of brief seizures, which start in infancy or early childhood, and is occasionally accompanied by varying degrees of cognitive impairment. The striking pattern of onset seizures at a young age, genetic testing and laboratory results, potential developmental delays or developmental regression and associated disorders, eases diagnosis.

<span class="mw-page-title-main">Mental retardation and microcephaly with pontine and cerebellar hypoplasia</span> Rare X-linked dominant genetic disorder

Mental retardation and microcephaly with pontine and cerebellar hypoplasia (MICPCH) – also known as mental retardation, X-linked, syndromic, Najm type (MRXSNA); X-linked intellectual deficit, Najm type; intellectual developmental disorder, X-linked, syndromic, Najm type; X-linked intellectual disability–microcephaly–pontocerebellar hypoplasia syndrome; and by variations of these terms – is a rare X-linked dominant genetic disorder of infants characterised by intellectual disability and pontocerebellar hypoplasia. It usually affects females; many males die before birth or not long after.

SYT1-associated neurodevelopmental disorder, also known as Baker-Gordon Syndrome, is a rare genetic disorder caused by mutations in the synaptotagmin-1 (SYT1) gene.

Barakat-Perenthaler syndrome is a rare neurodevelopmental genetic disorder, presenting with a severe epileptic encephalopathy, developmental delay, Intellectual disability, progressive microcephaly and visual disturbance. It is listed by the standard reference, Online Mendelian Inheritance in Man (OMIM) as #618744. and classified as EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 83; EIEE83. It was first described in 2019 by Dr. Stefan Barakat and his team at the Erasmus University Medical Center in Rotterdam in the journal Acta Neuropathologica; the most recent reviews were published in Epilepsy Currents. and Trends in Endocrinology and Metabolism

SYNGAP1-related intellectual disability is a monogenetic developmental and epileptic encephalopathy that affects the central nervous system. Symptoms include intellectual disability, epilepsy, autism, sensory processing deficits, hypotonia and unstable gait.

GRIN disorders are a group of neurodevelopmental disorders that result from mutations in genes coding for subunits of an N-methyl-D-aspartate (NMDA) receptor, which leads to dysfunction of glutamate signaling. GRIN disorders are universally characterized by a varying degree of developmental delay and intellectual disability, as well as epileptic seizures. Other clinical features vary depending on the affected gene and may include muscular hypotonia, spasticity, and movement disorders. GRIN disorders are confirmed with genetic testing and managed symptomatically since there is currently no cure for the disorder.

Jordan's Syndrome (JS) or PPP2R5D-related intellectual disability is a rare autosomal dominant neurodevelopmental disorder caused by de novo mutations in the PPP2R5D gene. It is characterized by hypotonia, intellectual disability, and macrocephaly. Children with JS may also have epilepsy or meet criteria for diagnosis with autism spectrum disorder.

<span class="mw-page-title-main">PURA syndrome</span> Medical condition

PURA syndrome, also known as PURA-related neurodevelopmental disorder, is a rare novel genetic disorder which is characterized by developmental and speech delay, neo-natal hypotonia, failure to thrive, excessive sleepiness, epilepsy, and other anomalies.

FBXW7 neurodevelopmental syndrome is a newly discovered genetic disorder which is characterized by gastrointestinal, brain, and muscle anomalies accompanied by intellectual disabilities and developmental delays.

SLC6A1 epileptic encephalopathy is a genetic disorder characterised by the loss-of-function of one copy of the human SLC6A1 gene. SLC6A1 epileptic encephalopathy can typically manifest itself with early onset seizures and it can also be characterised by mild to severe learning disability. Not all manifestations of the conditions are present in one given patient.

CHAMP1-associated intellectual disability syndrome, also known as autosomal dominant intellectual disability type 40, is a rare genetic disorder characterized by intellectual disabilities, developmental delays, facial dysmorphisms, and other anomalies.

<span class="mw-page-title-main">Beck–Fahrner syndrome</span> Rare genetic disorder

Beck–Fahrner syndrome, also known as BEFAHRS and TET3 deficiency, is a rare genetic disorder caused by mutations of the TET3 gene. It can occur de novo or can be inherited in an autosomal dominant manner. Mutations in the TET3 gene disrupts DNA demethylation during early embryogenesis and neural development. Most common clinical presentation includes global developmental delay, psychomotor retardation, neurodevelopmental disorders, hypotonia, epilepsy and dysmorphic features. It is diagnosed using molecular and genetic testing in setting of typical symptoms. Management is supportive and intended to improve quality of life.

<span class="mw-page-title-main">High anterior hairline</span> Medical condition

High anterior hairline is a condition in which the frontal hairline which defines the top and sides of the forehead is unusually high. This can mean that either the distance between the trichion (hairline) and glabella is more than 2 SD above the mean, or that this distance is apparently (subjectively) increased.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 Dyment, David; Lines, Matthew; Innes, A Micheil (2023-02-23). "TRPM3-Related Neurodevelopmental Disorder". University of Washington, Seattle. PMID   36821706.{{cite journal}}: Cite journal requires |journal= (help)
  2. 1 2 3 4 5 6 7 8 9 Burglen, Lydie; Van Hoeymissen, Evelien; Qebibo, Leila; et al. (2023). "Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders". eLife. 12. doi: 10.7554/elife.81032 . PMC   9886277 . PMID   36648066.
  3. 1 2 Dyment, David A.; Terhal, Paulien A.; Rustad, Cecilie F.; et al. (2019). "De novo substitutions of TRPM3 cause intellectual disability and epilepsy". European Journal of Human Genetics. 27 (10): 1611–1618. doi:10.1038/s41431-019-0462-x. PMC   6777445 . PMID   31278393. S2CID   195804345.
  4. 1 2 3 Lines, Matthew A.; Goldenberg, Paula; Wong, Ashley; et al. (2022). "Phenotypic spectrum of the recurrent TRPM3 p.( Val837Met ) substitution in seven individuals with global developmental delay and hypotonia". American Journal of Medical Genetics Part A. 188 (6): 1667–1675. doi:10.1002/ajmg.a.62673. PMID   35146895. S2CID   246749002.
  5. 1 2 Zhao, Siyuan; Yudin, Yevgen; Rohacs, Tibor (2020). "Disease-associated mutations in the human TRPM3 render the channel overactive via two distinct mechanisms". eLife. 9. doi: 10.7554/elife.55634 . PMC   7255801 . PMID   32343227.
  6. 1 2 Van Hoeymissen, Evelien; Held, Katharina; Nogueira Freitas, Ana Cristina; Janssens, Annelies; Voets, Thomas; Vriens, Joris (19 May 2020). "Gain of channel function and modified gating properties in TRPM3 mutants causing intellectual disability and epilepsy". eLife. 9: e57190. doi: 10.7554/eLife.57190 . ISSN   2050-084X. PMC   7253177 . PMID   32427099.
  7. ↑ Becker, Lena‐Luise; Horn, Denise; Boschann, Felix; et al. (2023). "Primidone improves symptoms in TRPM3-linked developmental and epileptic encephalopathy with spike-and-wave activation in sleep". Epilepsia. 64 (5): e61–e68. doi: 10.1111/epi.17586 . PMID   36929095. S2CID   257581570.
  8. ↑ Krügel, Ute; Straub, Isabelle; Beckmann, Holger; Schaefer, Michael (2017). "Primidone inhibits TRPM3 and attenuates thermal nociception in vivo". Pain. 158 (5): 856–867. doi:10.1097/j.pain.0000000000000846. PMC   5402713 . PMID   28106668.
  9. ↑ Gauthier, LW; Chatron, N; Cabet, S; Labalme, A; Carneiro, M; Poirot, I; Delvert, C; Gleizal, A; Lesca, G; Putoux, A (November 2021). "Description of a novel patient with the TRPM3 recurrent p.Val837Met variant". European Journal of Medical Genetics. 64 (11): 104320. doi: 10.1016/j.ejmg.2021.104320 . PMID   34438093.
  10. ↑ Kang, Q; Yang, L; Liao, H; Yang, S; Kuang, X; Ning, Z; Liao, C; Chen, B (1 June 2021). "A Chinese patient with developmental and epileptic encephalopathies (DEE) carrying a TRPM3 gene mutation: a paediatric case report". BMC Pediatrics. 21 (1): 256. doi: 10.1186/s12887-021-02719-8 . PMC   8167971 . PMID   34074259.
  11. ↑ Sundaramurthi, JC; Bagley, AM; Blau, H; Carmody, L; Crandall, A; Danis, D; Gargano, M; Gustafson, AG; Raney, EM; Shingle, M; Davids, JR; Robinson, PN (8 September 2023). "De novo TRPM3 missense variant associated with neurodevelopmental delay and manifestations of cerebral palsy". Cold Spring Harbor Molecular Case Studies: mcs.a006293. doi: 10.1101/mcs.a006293 . PMID   37684057. S2CID   261620692.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.